Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this phase III clinical study is to compare the efficacy and safety
of the fixed combination of pyronaridine artesunate (Pyramax®, PA) with that of the
combination of mefloquine plus artesunate (MQ + AS) in children and adults with uncomplicated
P falciparum malaria in South East Asia, India and Africa.